Cargando…

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

The clinical significance of BRAF alterations in well-differentiated (WD) metastatic pancreatic neuroendocrine tumor (panNET) is unknown, but BRAF-mutated panNET could represent a subset characterized by an identifiable and clinically actionable driver. Following the identification of two patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen, Amy, Qin, Alice Can Ran, Raj, Nitya, Wang, Jiawan, Uddin, Sharmeen, Yao, Zhan, Tang, Laura, Meyers, Paul A., Taylor, Barry S., Berger, Michael F., Yaeger, Rona, Reidy-Lagunes, Diane, Pratilas, Christine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546234/ https://www.ncbi.nlm.nih.gov/pubmed/31158244 http://dx.doi.org/10.1371/journal.pone.0217399

Ejemplares similares

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
por: Obasaju, Patience, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014)

SUN-911 Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
por: Madhavan, Parvathy, et al.
Publicado: (2020)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Conferring specificity on the ubiquitous Raf/MEK signalling pathway
por: O'Neill, E, et al.
Publicado: (2004)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

The mechanism of activation of MEK1 by B-Raf and KSR1
por: Maloney, Ryan C., et al.
Publicado: (2022)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
por: Wang, Xiaojuan, et al.
Publicado: (2020)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

Aberrant expression of the COX2/PGE(2) axis is induced by activation of the RAF/MEK/ERK pathway in BRAF(V595E) canine urothelial carcinoma
por: Yoshitake, Ryohei, et al.
Publicado: (2020)

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor
por: Lemberg, Kathryn M., et al.
Publicado: (2020)

FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways
por: Rabik, Cara A., et al.
Publicado: (2020)

Global view of the RAF-MEK-ERK module and its immediate downstream effectors
por: Santini, Cristina C., et al.
Publicado: (2019)

Porcine deltacoronavirus activates the Raf/MEK/ERK pathway to promote its replication
por: Jeon, Ji Hyun, et al.
Publicado: (2020)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
por: Chatelle, Claire V., et al.
Publicado: (2016)

Hepatic Hilar Block as an Adjunct to Transarterial Embolization of Neuroendocrine Tumors: A Retrospective Review of Safety and Efficacy
por: Jain, Samagra, et al.
Publicado: (2023)

Author Correction: Aberrant expression of the COX2/PGE(2) axis is induced by activation of the RAF/MEK/ERK pathway in BRAF(V595E) canine urothelial carcinoma
por: Yoshitake, Ryohei, et al.
Publicado: (2020)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4k2fjjd0ioshno5lu8n247dt3p